POMDOCTOR Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.5M
- Price
- $0.8097
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.61%
- Volume
- 62.7K
About
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Quick stats
Shares outstanding9.3M
Computed float—
Float / sharesUnknown
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001877971
Websitehttps://www.7lk.com
AI Summary
AI-generated1/32
minorneutraloperations update
POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization
Pomdoctor provided an update on its AI-enabled chronic disease management ecosystem, citing continued optimization of its proprietary AI system and expanded real-world data applications.
The company is commercializing RWD capabilities through pharmaceutical real-world studies, B2B healthcare data services, and third-party collaborations, which it identifies as a core value driver in its four-tier revenue structure.
It is also running integrated in-hospital and out-of-hospital chronic disease management pilots designed to extend care beyond individual clinical encounters.
The release contains no new financial metrics, contracts, or regulatory developments; it is a strategic positioning update from a small-cap digital healthcare company.